By 2023, the top 10 products which are expected to occupy more than 40% of the market will be non-insulin products. The highest unmet need in the T2DM space is the inability to maintain good glycaemic control in the long-term. Existing treatments are capable of reducing complication rates but are unable to adequately address this unmet need. By 2040 it is expected that 625 million people will have diabetes.
The seven major Diabetes markets by revenues are the US, France, Germany, Italy, Spain, the UK, and Japan. China has the highest prevalence globally. Pramana has filed patents in all of these jurisdictions. Emerging epidemic markets in the MENA region with 39 million cases in 2017 with an epidemic concentration in the Middle East.
Key Players and their Leading Products
Byetta was the first U.S. Food and Drug Administration approved glucagon-like peptide-1 receptor agonist in the United States for use in adult patients for the treatment of Type 2DM.
David Parkes Ph.D, a member of Pramana's Scientific Team,
led preclinical development of Exenatide, a first-in-class treatment for Type 2 Diabetes, now approved worldwide as Byetta and Bydureon